Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIO-1: Lucitanib + Nivolumab in Advanced Solid Tumors and Gynecologic Cancers
NCT04042116Phase 2Suspended
- Sponsor
- Clovis Oncology
- Start
- Jul 2019
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of lucitanib in solid tumor (advanced stage), endometrial cancer (EC), ovarian cancer, Cervical Cancer (CC), clear cell carcinoma (CCC), sponsored by Clovis Oncology. Started Jul 2019; status: suspended.
02
Drugs
lucitanib
03
Conditions
solid tumor (advanced stage)endometrial cancer (EC)ovarian cancerCervical Cancer (CC)clear cell carcinoma (CCC)
Beyond the preview
Go deeper on NCT04042116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04042116.